USA Pharma News | Healthcare News 4/5

JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER

ipharmaservices

Jun 27, 2020

US FDA approved Epizyme’s Tazverik for Relapsed/Refractory Follicular Lymphoma

ipharmaservices

Jun 20, 2020

Eli Lilly Lyumjev secures the US FDA approval for type-1 and type-2 diabetes

ipharmaservices

Jun 19, 2020

Novartis Ilaris to be the first FDA approved treatment for Adult-Onset Still’s Disease (AOSD)

ipharmaservices

Jun 19, 2020

FDA approved Novartis Cosentyx and Lilly’s Taltz for nr-axSpA in June

ipharmaservices

Jun 19, 2020

AMERICAN ACADEMY OF DERMATOLOGY CONFERENCE 2020

ipharmaservices

Jun 17, 2020

Viela Bio’s Uplizna received FDA approval for neuromyelitis optica spectrum disorder

ipharmaservices

Jun 13, 2020

Opdivo approved in the US for ESCC

ipharmaservices

Jun 12, 2020

Taltz was approved in the U.S. for non-radiographic axial spondyloarthritis

ipharmaservices

Jun 6, 2020

FDA approved Merck’s Recarbrio to treat hospital acquired pneumonia

ipharmaservices

Jun 5, 2020

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

ipharmaservices

Jun 3, 2020

#ASCO2020

ipharmaservices

May 31, 2020

FDA approved Eli Lilly’s Retevmo for advanced RET-driven lung and thyroid cancers

ipharmaservices

May 18, 2020

Deciphera Pharmaceuticals’ Qinlock (ripretinib) received the US FDA approval for advanced GIST

ipharmaservices

May 16, 2020

FDA approved Novartis’ Tabrecta for NSCLC with METex14

ipharmaservices

May 10, 2020

PFIZER AND BIONTECH STARTS THE CLINICAL TRIALS OF COVID-19 VACCINE

ipharmaservices

May 10, 2020

AstraZeneca’s approved Koselugo by US FDA for neurofibromatosis type 1

ipharmaservices

Apr 13, 2020

FDA approved a new treatment for a rare soft tissue cancer, epithelioid sarcoma

ipharmaservices

Jan 27, 2020

Trump administration takes first step in implementing provisional law to control drug prices

ipharmaservices

Dec 18, 2019

AstraZeneca’s Farxiga received fast track designation from US FDA

ipharmaservices

Sep 17, 2019

iPharmaCenter

ipharmacenter Consulting services

JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER

US FDA approved Epizyme’s Tazverik for Relapsed/Refractory Follicular Lymphoma

Eli Lilly Lyumjev secures the US FDA approval for type-1 and type-2 diabetes

Novartis Ilaris to be the first FDA approved treatment for Adult-Onset Still’s Disease (AOSD)

FDA approved Novartis Cosentyx and Lilly’s Taltz for nr-axSpA in June

AMERICAN ACADEMY OF DERMATOLOGY CONFERENCE 2020

Viela Bio’s Uplizna received FDA approval for neuromyelitis optica spectrum disorder

Opdivo approved in the US for ESCC

Taltz was approved in the U.S. for non-radiographic axial spondyloarthritis

FDA approved Merck’s Recarbrio to treat hospital acquired pneumonia

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

#ASCO2020

FDA approved Eli Lilly’s Retevmo for advanced RET-driven lung and thyroid cancers

Deciphera Pharmaceuticals’ Qinlock (ripretinib) received the US FDA approval for advanced GIST

FDA approved Novartis’ Tabrecta for NSCLC with METex14

PFIZER AND BIONTECH STARTS THE CLINICAL TRIALS OF COVID-19 VACCINE

AstraZeneca’s approved Koselugo by US FDA for neurofibromatosis type 1

FDA approved a new treatment for a rare soft tissue cancer, epithelioid sarcoma

Trump administration takes first step in implementing provisional law to control drug prices

AstraZeneca’s Farxiga received fast track designation from US FDA